

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

INA-6

RRID:CVCL_5209

Type: Cell Line

Proper Citation

RRID:CVCL_5209

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5209

Proper Citation: RRID:CVCL_5209

Description: Cell line INA-6 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:10936422](#), [PMID:11920233](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:19621390](#), [PMID:22806891](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Characteristics: IL6 dependent., Characteristics: Produces Ig kappa., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: INA-6

Synonyms: INA6

Cross References: BTO:BTO_0004745, EFO:EFO_0005386, BioSample:SAMN10989605, cancercellines:CVCL_5209, Cell_Model_Passport:SIDM01555, Cosmic:1424216, Cosmic:1483075, Cosmic:2081383, DepMap:ACH-000512, DSMZ:ACC-862, DSMZCellDive:ACC-862, Wikidata:Q54897699

ID: CVCL_5209

Record Creation Time: 20220427T220636+0000

Ratings and Alerts

No rating or validation information has been found for INA-6.

No alerts have been found for INA-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. *Molecular cancer therapeutics*, 25(6), 1016.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Kuric M, et al. (2024) Modeling Myeloma Dissemination In Vitro with hMSC-interacting Subpopulations of INA-6 Cells and Their Aggregation/Detachment Dynamics. *Cancer research communications*, 4(4), 1150.

Aass KR, et al. (2022) Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells. *iScience*, 25(1), 103605.